- Home
- ENTX vs MIST Comparison
ENTX vs MIST Comparison
Compare ENTX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTX | MIST |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 146.9M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ENTX | MIST |
|---|---|---|
| Price | $2.96 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $8.00 |
| AVG Volume (30 Days) | 344.3K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.88 |
| 52 Week High | $4.20 | $3.06 |
Technical Indicators
Market Signals| Indicator | ENTX | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 31.89 |
| Support Level | $2.73 | N/A |
| Resistance Level | $3.10 | $1.42 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 46.81 | 5.29 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.